Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2B

Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The…

Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2 Billion

Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The…

Cigna-Humana Merger Is Likely to Face Antitrust Challenge

From a financial perspective, a Cigna-Humana megamerger makes a lot of sense.  Cigna has a huge…

Gene Editing Will Change Medicine—and Maybe Health Investing Too

It usually takes time for scientific discoveries in the lab to make their way to the…

Sam Bankman-Fried to Take the Stand in Fraud Trial

Updated Oct. 25, 2023 11:32 am ET FTX founder Sam Bankman-Fried will testify at his criminal…

Sam Bankman-Fried Took Risks at FTX. Will He Bet on His Own Testimony?

FTX founder Sam Bankman-Fried, known for his appetite for risky bets, is mulling perhaps his biggest…

Ozempic Boom Is an Opportunity for Health Insurers

You would think a new class of high-price weight loss drugs taken by millions of Americans…

WSJ News Exclusive | Starboard Takes 5%-Plus Stake in Contract-Research Firm Fortrea

The activist investor plans to push for changes that could boost margins among other initiatives aimed…

Pharmacy Giant Walgreens Names Tim Wentworth as New CEO

The incoming chief executive faces a tough challenge, with a core business under pressure due to…

Opinion | The FDA’s Laboratory Land Grab

The agency wants to treat academic and other lab tests like medical devices. It’s a lousy…